

**The Walter P. Scheffe Continuing Pharmaceutical Education Series
October 22-23, 2022 | University of Oklahoma College of Pharmacy | OKC, OK**

SYLLABUS

October 22, 2022 – 8 contact hours (0.8 CEUs) total

7:30-7:55am **Registration/Continental Breakfast**

7:55-8:00am **Introduction**

8:00-10:00am **Therapy Update: Managing Dementia, Delirium, and Depression in Older Individuals* (A)**

ACPE # 0053-0000-22-026-L01-P | 2 contact hours (0.2 CEUs)

Keith Swanson, Pharm.D., Associate Professor, OU College of Pharmacy, OKC

At the completion of this activity, pharmacists will be able to identify options for treating cognitive and behavioral symptoms in dementia and delirium, compare both positive and negative outcomes associated with medications used to treat dementia and delirium, and apply options for treating initial and treatment resistant depression in older individuals.

10:00-10:15am **Break**

10:15-12:15pm **Updates in Diabetes Care* (K)**

ACPE # 0053-0000-22-027-L01-P | 2 contact hours (0.2 CEUs)

Katherine O'Neal, Pharm.D., M.B.A., Associate Professor, OU College of Pharmacy, OKC

At the completion of this activity, pharmacists will be able to describe pertinent updates to the 2022 American Diabetes Association Standards of Medical Care, summarize key evidence from trials supporting expanded FDA indications for anti-glycemic agents, compare and contrast GLP-1 agonists and SGLT2 inhibitors, and describe newly approved medications, formulations, and indications related to diabetes standards of care.

12:15-12:45pm **Lunch**

12:45-2:15pm **Flowing Through Updates in the Treatment in Heart Failure* (A)**

ACPE # 0053-0000-22-028-L01-P | 1.5 contact hours (0.15 CEUs)

Jordan Perrine, Pharm.D., M.B.A., BCPS, Assistant Professor, OU College of Pharmacy, OKC

At the completion of this activity, pharmacists will be able to compare and contrast the 2022 ACC/AHA/HFSA Heart Failure Guidelines to previous recommendations, analyze recent landmark trials published in HFrEF and HFpEF, and summarize evidence that impacts recent practice change in the treatment of heart failure.

2:15-2:30pm **Break**

2:30-3:30pm **Oklahoma State Board of Pharmacy Law Update 2022* (K)**

ACPE # 0053-0000-22-029-L03-P | 1 contact hour (0.1 CEU)

Keevie Ridener, Pharm.D., D.Ph., Pharmacist Compliance Officer, OSBP, OKC

At the completion of this activity, pharmacists will be able to identify recent updates to the Oklahoma State Board of Pharmacy rules and laws, summarize current state regulations in regards to dispensing controlled substances, and explain how recent law changes may impact the practice of pharmacy.

3:30-5:00pm **The 'Dirty Dozen' - Herbal Products to Stay Away From* (A)**

ACPE # 0053-0000-22-030-L99-P | 1.5 contact hours (0.15 CEUs)

Kristie Edelen, Pharm.D., D.A.B.A.T., Assistant Managing Director, OCPDI, OKC

At the completion of this activity, pharmacists will be able to define the Dietary Supplement Health and Education Act of 1994, identify three general mechanisms underlying why an herb might be toxic, and distinguish the toxic active ingredient in three specific herbal products

5:00-5:05pm **Closing Remarks/Evaluation**

October 23, 2022 – 7 contact hours (0.7 CEUs) total

7:30-7:55am **Registration/Continental Breakfast**

7:55-8:00am **Introduction**

8:00-10:00am **Major Depressive Disorder and Bipolar Disorder: A Primer for Community Pharmacists* (K)**

ACPE # 0053-0000-22-031-L01-P | 2 contact hours (0.2 CEUs)

Tammy Lambert, Pharm.D., Ph.D., Clinical Assistant Professor, OU College of Pharmacy, OKC

At the completion of this activity, pharmacists will be able to describe the clinical features and symptoms that support a diagnosis of MDD, compare and contrast mood episodes and clinical features required for a diagnosis of BP I, BP II, and cyclothymic disorders, identify health conditions and medications that can induce or worsen MDD symptoms and BP symptoms, summarize appropriate pharmacotherapies and non-pharmacological treatments for MDD and BP disorders, and recognize screening tools available to use with patients with MDD or BP to improve medication adherence and health outcomes.

10:00-10:15am **Break**

10:15-11:15am **Pharmacists at the Bedside: Revolutionizing Healthcare Delivery* (K)**

ACPE # 0053-0000-22-032-L04-P | 1 contact hour (0.1 CEU)

Holly Herring, Pharm.D., BCPS, Associate Vice President of Pharmacy, OU Health, OKC

At the completion of this activity, pharmacists will be able to define a safe and effective medication management system, identify a gap in the current healthcare delivery model in hospitals, and describe how pharmacists can improve patient care at the bedside.

11:15-12:15pm **The KIDs List: Agents to Avoid and Use with Caution in Children* (K)**

ACPE # 0053-0000-22-033-L01-P | 1 contact hour (0.1 CEU)

Jamie Miller, Pharm.D., BCPPS, FPPA, Professor of Pharmacy Practice, OU College of Pharmacy, OKC

At the completion of this activity, pharmacists will be able to identify the purpose of the KIDs List, explain why use of benzocaine, codeine, diphenoxylate/atropine, and valproic acid should be avoided in infants and/or children, and describe why ceftriaxone, loperamide, sulfamethoxazole/trimethoprim, and tetracyclines should be used with caution in infants/children.

12:15-12:45pm **Lunch**

12:45-2:45pm **Energy Management for Working Professionals* (K)**

ACPE # 0053-0000-22-034-L99-P | 2 contact hours (0.2 CEUs)

Michael Smith, Ph.D., R.Ph., FAPhA, NBC-HWC, Associate Dean for Academic and Student Affairs, OU College of Pharmacy, OKC

At the completion of this activity, pharmacists will be able to describe four dimensions of energy sources in human systems, list various activities related to each dimension that impact energy management, and identify at least one activity to utilize to increase energy capacity.

2:45-3:00pm **Break**

3:00-4:00pm **Updates in Allergic Rhinitis and Conjunctivitis: When to Recommend the New Rx-to-OTC Switches* (A)**

ACPE # 0053-0000-22-035-L01-P | 1 contact hour (0.1 CEU)

Paul Boylan, Pharm.D., BCPS, Assistant Professor, OU College of Pharmacy, OKC

At the completion of this activity, pharmacists will be able to compare oral, nasal, and ophthalmic nonprescription antihistamines, classify a patient's allergic rhinitis or conjunctivitis given their signs and symptoms, and choose appropriate nonprescription medications for the treatment of allergic rhinitis and conjunctivitis.

4:00-4:05pm **Closing Remarks/Evaluation**

Target Audience

This continuing education program is intended for pharmacists in any practice setting.

Continuing Education

*Denotes sessions of Continuing Education credit provided by the University of Oklahoma College of Pharmacy. Please note next to the ACPE # the type of activity: (K) = Knowledge-based & (A) = Application-based. These activities are structured to meet knowledge- and/or application-based education needs. A knowledge-based activity is for participants to acquire factual knowledge. An application-based activity is for participants to apply the information learned in the allotted timeframe. Information in all continuing education activities is based on evidence as accepted in the literature by the healthcare professions.



The University of Oklahoma College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation.

Awarding Credit

This seminar offers a total of 15 contact hours (1.5 CEUs) of ACPE-accredited continuing pharmacy education credit accepted by the Oklahoma Board of Pharmacy and most other states. Credit will be earned based on the participation in individually accredited activities. Full attendance and participation are required before obtaining CPE credit. Partial credit will not be awarded. Any individual who is over 10 minutes late or leaves early will not be granted credit. The University of Oklahoma College of Pharmacy, as an ACPE-accredited provider, is required to report all credit through CPE Monitor. Credit will be available online to participants within four weeks. A notification email will be sent to participants when credit is uploaded. It is your responsibility to confirm that your credit has been uploaded correctly by 12/11/22. You must notify Cassidy Roberts of any errors or corrections before this date, as ACPE guidelines prohibit providers from issuing or modifying credit more than 60 days after the activity for any reason. The initial release dates are 10/22/22 and 10/23/22. For successful completion and

subsequent awarding of credit, the attendance verification procedure will require each participant to: sign in on the morning and afternoon sign-in sheet, provide NABP e-Profile ID # and month and day of birth, participate in the learning assessments, return nametag at the end of the final session attended, and complete the online program evaluation.

Registration, Refund and Grievance Policy

Pre-registration is suggested to allow the College to provide the appropriate faculty and materials necessary to meet the program objectives. Early registration is \$135/day and will be accepted until 10/21/22. Registration includes all program materials, continental breakfast, lunch and refreshments. A link to the activity materials will be provided online for registered participants to download and/or print. The College reserves the right to limit registrations or cancel courses. There are no refunds. For any questions, concerns or grievances associated with this educational activity, please contact (405) 271-6194 or Cassidy-Roberts@ouhsc.edu. You may contact the College for a copy of the grievance policy.

Commercial Support

Commercial support is financial, or in-kind contribution given by an ineligible company, which is used to pay all or part of the costs of a CPE activity. No commercial support was received for this program. Initiation and development of this continuing pharmaceutical education series is made possible through the kind and generous establishment by Mr. Scheffe of the Walter P. Scheffe Endowment for Pharmaceutical Education.

Financial Disclosure and Mitigation Report

The University of Oklahoma College of Pharmacy endorses the ACPE Standards for Integrity and Independence in Accredited Continuing Education. All accredited activities must be balanced, objective, independent of commercial bias and must promote improvements or quality in healthcare. All recommendations must be based on evidence accepted within the medical profession. We require that everyone in a position to control the content of an accredited educational activity disclose all financial relationships with ineligible companies of any amount within the last 24 months. The University of Oklahoma College of Pharmacy will identify, review and mitigate all relevant financial relationships that anyone in control of content disclose prior to an educational activity being delivered to learners. This policy is designed to provide the target audience with an opportunity to review any affiliations for the purpose of determining the potential presence of bias or influence over educational content.

None of the faculty or planning committee members have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Paul Boylan
Kristie Edelen
Holly Herring

Tammy Lambert
Jamie Miller
Katherine O'Neal

Jordan Perrine
Keevie Ridener
Cassidy Roberts

Michael Smith
Keith Swanson